Search

Funding will Support Development of AI Clinician, Using Spatial Computing.

AseBio has been a key player in the journey taken over these 25 years by biotechnology in Spain, positioning itself as a strategic agent in the face of challenges and future prospects.

The objective of this study was to analyze the impact of glaucoma in ambulatory centers and hospitals in Spain over the past decade and to measure the associated direct medical costs and incidence.

Due to Spain's scientific and technological potential, both in the public and private sectors, our country has the responsibility to give a new boost to the biotechnological sector and thus respond to

Results across all efficacy endpoints consistently favored vafidemstat over placebo. Global Statistical Test (GST p-values) confirms consistent trend across efficacy endpoints.

To drive research efforts, it is key to choose world-class controls, and to understand them not as mere tools, but as indispensable assets that guarantee the highest quality standards, saving time and

He highlights his participation in the 7º Sachs Annual Neuroscience Innovation Forum, 13º Annual LifeSci Advisors Corporate Access Event, Biotech Showcase-2024, 42º Annual J.P. Morgan Healthcare

In 2022, the Inflation Reduction Art (IRA) became US law with the aim to reduce drug costs.

The SAB will provide strategic guidance on the company's research and development efforts and strategy, particularly focused on the FiCAT gene writing platform that improves the development of gene

In the General Assembly of AseBio, new vice-presidents have also been elected: Carlos Buesa, CEO of Oryzon (First Vice-presidency); Cristina Nadal, Policy Executive Director of MSD Spain (Second Vice

Recent company sales grow by 70%, reflecting expanded capabilities and industry recognition of VIVEbiotech’s expertise in manufacturing lentiviruses, now used in in 70% of global ex-vivo CGT clinical

Innovation has enabled breakthroughs such as recent drugs for Alzheimer's disease, the use of devices that stimulate brain function for the treatment of certain pathologies or Virtual Reality for post

Over the last 40 years, biotechnology has shaped the landscape of medicine, as evidenced by the fact that 69% of drugs in development are a result of biotechnological advancements.

Meet BeCytes Biotechnologies, our new member. We talked with Estephan Arredondo Córdova, Technical Director

Meet JORI & ARMENGOL, our new ally. We talked to María Sanjuanbenito, ejecutiva de Cuentas.

In a context where these innovations are advancing rapidly, Spain needs to modernize programs and instruments that enable harnessing our scientific and technological potential, transforming it into

We spoke with Ana Isabel Jiménez, General Director of Sylentis, to learn how mRNA technology already provides alternative pathways that allow targeting key proteins involved in the development of

To explore Oryzon’s clinical candidate ORY-4001 in ALS. The ALS Association to provide 500,000 USD funding.

The company is developing a proprietary platform technology to design new drugs targeting protein allosteric sites to treat cancer and potentially many other diseases.

All biobanks in the RVB currently have a quality management system certified according to the ISO 9001:2015.

The CrisBio® platform uses a totally different protein expression system, since it uses the pupae of the Trichoplusia NI moth as natural bioreactors for the production of enzymes and recombinant